-
1.发明授权Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists 有权用α-2B肾上腺素能受体激动剂激活调节性T细胞的方法公开(公告)号：US08575207B2
公开(公告)日：2013-11-05
申请号：US13207801
申请日：2011-08-11
IPC分类号： A61K31/415
CPC分类号： A61K31/4164 , A61K31/17 , A61K31/4168 , A61K31/4178 , A61K31/421 , A61K31/4439
摘要： Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist.
摘要翻译： 本文公开了通过施用α2受体激动剂上调调节性T细胞并治疗可受益于这种上调的疾病的方法。
-
2.发明授权Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists 失效用α-2肾上腺素能受体激动剂治疗感觉异常症的方法公开(公告)号：US08455548B2
公开(公告)日：2013-06-04
申请号：US12680640
申请日：2008-10-14
IPC分类号： A01N47/28 , A61K31/17 , C07C335/00
CPC分类号： A61K31/17 , A61K31/4174 , A61K31/4439
摘要： Disclosed herein is a method of treating sensorimotor disorders comprising administering to a subject in need of such treatment an alpha-2 receptor agonist lacking significant alpha-2A receptor activity.
摘要翻译： 本文公开了一种治疗感觉运动障碍的方法，包括向需要这种治疗的受试者施用不具有显着α-2A受体活性的α-2受体激动剂。
-
公开(公告)号：US09040532B2
公开(公告)日：2015-05-26
申请号：US13500501
申请日：2010-10-06
申请人： Ken Chow , Liming Wang , Wenkui K. Fang , Evelyn G. Corpuz , Santosh C. Sinha , Daniel W. Gil , Mohammad I. Dibas , John E. Donello
发明人： Ken Chow , Liming Wang , Wenkui K. Fang , Evelyn G. Corpuz , Santosh C. Sinha , Daniel W. Gil , Mohammad I. Dibas , John E. Donello
IPC分类号： A61K31/40 , A61K31/498 , A61K31/4184 , A61K31/4709 , C07D403/12 , C07D401/12 , C07D207/22 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04
CPC分类号： A61K31/498 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/4184 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4709 , C07D207/22 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , Y10S514/913
摘要： Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described.
摘要翻译： 本文描述的化合物可用于通过调节一种或多种α-肾上腺素能受体来治疗疾病和病症。 化合物可以包括萘，喹啉，苯并咪唑或异喹啉作为核心结构。 描述制备，使用和配制这些化合物的方法。
-
![Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol](/abs-image/US/2013/07/23/US08492557B2/abs.jpg.150x150.jpg)
4.发明授权Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol 有权[3-（1-（1H-咪唑-4-基）乙基）-2-甲基苯基]甲醇的酯前体药物公开(公告)号：US08492557B2
公开(公告)日：2013-07-23
申请号：US13233891
申请日：2011-09-15
申请人： Ken Chow , Liming Wang , Michael E. Garst , John E. Donello , Daniel W. Gil , Mohammad I. Dibas
发明人： Ken Chow , Liming Wang , Michael E. Garst , John E. Donello , Daniel W. Gil , Mohammad I. Dibas
IPC分类号： C07D233/64 , A61K31/216
CPC分类号： A61K31/4174 , A61K9/0014 , A61K31/4164 , C07D233/64 , Y10S514/912
摘要： The present invention relates to novel compounds, ester pro-drugs of [3-(1-1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals in the treatment of conditions mediated by adrenergic receptors.
摘要翻译： 本发明涉及[3-（1-（1H-咪唑-4-基）乙基）-2-甲基苯基]甲醇的新型化合物酯前体药物，其制备方法，含有它们的药物组合物及其用途 药物治疗由肾上腺素能受体介导的病症。
-
公开(公告)号：US08217059B2
公开(公告)日：2012-07-10
申请号：US12883949
申请日：2010-09-16
申请人： Daniel W. Gil , John E. Donello
发明人： Daniel W. Gil , John E. Donello
CPC分类号： A61K31/40 , A61K31/4025 , A61K31/4427 , A61K31/4523 , A61K31/4709
摘要： Disclosed are methods of treating spasticity by administering to a patient in need of such treatment a compound having the following formula:
摘要翻译： 公开了通过向需要这种治疗的患者施用具有下式的化合物来治疗痉挛的方法：
-
![ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL](/abs-image/US/2012/05/17/US20120122945A1/abs.jpg.150x150.jpg)
6.发明申请ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL 有权[3-（1-（1H-咪唑-4-基）乙基）-2-甲基苯基]甲醇的酯化物公开(公告)号：US20120122945A1
公开(公告)日：2012-05-17
申请号：US13233891
申请日：2011-09-15
申请人： Ken Chow , Liming Wang , Michael E. Garst , John E. Donello , Daniel W. Gil , Mohammad I. Dibas
发明人： Ken Chow , Liming Wang , Michael E. Garst , John E. Donello , Daniel W. Gil , Mohammad I. Dibas
IPC分类号： A61K31/4174 , A61P27/02 , C07D233/64
CPC分类号： A61K31/4174 , A61K9/0014 , A61K31/4164 , C07D233/64 , Y10S514/912
摘要： The present invention relates to novel compounds, ester pro-drugs of [3-(1-1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals in the treatment of conditions mediated by adrenergic receptors.
摘要翻译： 本发明涉及[3-（1-（1H-咪唑-4-基）乙基）-2-甲基苯基]甲醇的新型化合物酯前体药物，其制备方法，含有它们的药物组合物及其用途 药物治疗由肾上腺素能受体介导的病症。
-
公开(公告)号：US08071636B2
公开(公告)日：2011-12-06
申请号：US12479129
申请日：2009-06-05
申请人： Wenkui K. Fang , Phong X. Nguyen , Ken Chow , Todd M. Heidelbaugh , Dario G. Gomez , Michael E. Garst , Santosh C. Sinha , Daniel W. Gil , John E. Donello
发明人： Wenkui K. Fang , Phong X. Nguyen , Ken Chow , Todd M. Heidelbaugh , Dario G. Gomez , Michael E. Garst , Santosh C. Sinha , Daniel W. Gil , John E. Donello
IPC分类号： A01N43/50 , A61K31/415 , C07D233/00
CPC分类号： A61K31/4168
摘要： Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, both acute and chronic.
摘要翻译： 本文描述了通过向受试者施用含有有效量的α-肾上腺素能调节剂的药物组合物来治疗受试者的病症或疾病的化合物和方法。 化合物和方法也可用于缓解急性和慢性疼痛的类型。
-
8.发明申请METHOD OF TREATING MOTOR DISORDERS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS 审中-公开用ALPHA-2B ADRENERGIC受体激动剂治疗电机障碍的方法公开(公告)号：US20110160265A1
公开(公告)日：2011-06-30
申请号：US12595191
申请日：2008-10-14
IPC分类号： A61K31/4164 , A61K31/17 , A61K31/4174 , A61K31/4168 , C07D233/58 , C07D233/64 , C07D233/42 , C07D233/48 , A61P25/14
CPC分类号： A61K31/17 , A61K31/4168 , A61K31/4174
摘要： Disclosed herein is a method of treating motor disorders comprising administering to a subject in need of such treatment an alpha-2 receptor agonist lacking significant alpha-2A receptor activity.
摘要翻译： 本文公开了一种治疗运动障碍的方法，包括向需要这种治疗的受试者施用不具有显着α-2A受体活性的α-2受体激动剂。
-
9.发明申请METHOD OF TREATING MOTOR DISORDERS WITH 4-(1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE 审中-公开用4-（1-（2,3-二甲基苯基）乙基）-1H-咪唑-2（3H） - 酮处理电机障碍的方法公开(公告)号：US20100216857A1
公开(公告)日：2010-08-26
申请号：US12680656
申请日：2008-10-14
IPC分类号： A61K31/4164 , A61P25/16 , A61P25/00
CPC分类号： A61K31/4174
摘要： Disclosed herein is a method of treating motor disorders comprising administering to a subject in need of such treatment 4-(1-(2,3-dimethylphenyl)ethyl)-1H-imidazole-2(3H)-thione.
摘要翻译： 本文公开了一种治疗运动障碍的方法，包括向需要这种治疗的受试者施用4-（1-（2,3-二甲基苯基）乙基）-1H-咪唑-2（3H） - 硫酮。
-
10.发明授权4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists 失效作为α2肾上腺素能激动剂的4-（杂芳基 - 甲基和取代的杂芳基 - 甲基） - 咪唑-2-硫酮公开(公告)号：US07399868B2
公开(公告)日：2008-07-15
申请号：US11232323
申请日：2005-09-20
申请人： Todd M. Heidelbaugh , Ken Chow , Phong X. Nguyen , Daniel W. Gil , John E. Donello , Michael E. Garst , Larry A. Wheeler
发明人： Todd M. Heidelbaugh , Ken Chow , Phong X. Nguyen , Daniel W. Gil , John E. Donello , Michael E. Garst , Larry A. Wheeler
IPC分类号： C07D233/42 , C07D403/06 , C07D209/04 , C07D209/02 , C07D487/04
CPC分类号： C07D471/04 , C07D401/06 , C07D403/06 , C07D405/06 , C07D409/06
摘要： Compounds of Formula 1 where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardivascular and/or sedatory activity. The compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2 adrenergic receptors. Compounds of Formula 1 which have no significant cardiovascular and/or sedatory activity are useful for treating pain and other conditions with minimal side effects.
摘要翻译： 变量具有本说明书中定义的含义的式1化合物是α2肾上腺素能受体的激动剂。 本公开内容的若干化合物优先于α2A2肾上腺素能受体是特异性或选择性的α2B2和/或α2C2N2肾上腺素能受体。 另外一些所要求保护的化合物没有或只有最小的血管内和/或镇静作用。 式1的化合物可用作哺乳动物（包括人）中用作治疗疾病的药物和/或缓解通过α2肾上腺素能受体的激动剂治疗的病症。 没有明显的心血管和/或镇静作用的式1化合物可用于治疗疼痛和其他具有最小副作用的病症。
-
-
-
-
-
-
-
-
-
搜索结果
113 条记录 (耗时 0.043 秒)
